2023-12-13 07:28:21 ET
DENVER, Colo., Dec 13, 2023 ( www.247marketnews.com )- Shattuck Labs, Inc. (NASDAQ: STTK) reported, this morning, initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.
Observations include a 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64%; 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral …
The post Positive Initial Topline Data from Ongoing Phase 1 Clinical Trial could make This Today’s Trade appeared first on 24/7 Market News .
For further details see:
Positive Initial Topline Data from Ongoing Phase 1 Clinical Trial could make This Today’s Trade